Struthers Richard Scott's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Sep 30, 2025
- Accession no.
- 0001658247-25-000011
- Filed
- Sep 30, 2025
- Trade date
- Sep 26, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $180.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Struthers Richard ScottCIK 0001746298 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 26, 2025 | Common Stock | SSaleDisposed | −4,000 | $45.00F2 | −$180,000 | 106,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $45.00 per share.
Referenced by the price of 1 transaction in Table I.